Google
Apple
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
NOVARTIS AG |
Real-time Estimate
Other stock markets
|
|
5-day change | 1st Jan Change | |
| 84.36 CHF | -0.62% | -1.09% | +0.72% | |
| Dec. 06 | Swiss Market Index Extends Gains as Dovish Narrative Lifts Sentiment | MT |
| Dec. 06 | Merck Shares Slump After Multiple Sclerosis Drug Fails in Late-Stage Trials | DJ |
ETFs positioned on Novartis AG
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 16.67% | 2,109 M€ | +2.21% | ||
| 16.47% | 2,038 M€ | +2.27% | - | |
| 15.31% | 9 M€ | 0.00% | - | |
| 15.06% | 455 M€ | +3.03% | - | |
| 15.06% | 1,165 M€ | -.--% | ||
| 14.75% | 1,906 M€ | +4.92% | ||
| 14.03% | 136 M€ | +7.93% | ||
| 13.50% | 603 M€ | +4.16% | ||
| 13.38% | 38 M€ | +8.05% | ||
| 13.36% | 131 M€ | +5.88% | ||
| 13.36% | 547 M€ | +1.00% | ||
| 13.36% | 58 M€ | +4.46% | ||
| 13.22% | 27 M€ | +0.97% | - | |
| 13.22% | 9 M€ | +6.52% | - | |
| 13.22% | 45 M€ | +7.35% | ||
| 13.22% | 5 M€ | +5.88% | - | |
| 13.22% | 385 M€ | +11.68% | - | |
| 13.22% | 342 M€ | +1.48% | - | |
| 13.22% | 1,255 M€ | +3.89% | ||
| 13.22% | 59 M€ | +4.57% | ||
| 13.22% | 113 M€ | +5.56% | ||
| 13.22% | 3 M€ | +3.19% | - | |
| 12.83% | 644 M€ | +5.38% | ||
| 12.79% | 492 M€ | +1.89% | ||
| 12.60% | 920 M€ | +1.06% | - | |
| 12.42% | 2,471 M€ | +1.11% | - | |
| 12.36% | 635 M€ | -.--% | ||
| 12.17% | 1,076 M€ | +9.11% | ||
| 10.40% | 121 M€ | -.--% | ||
| 9.07% | 199 M€ | -.--% | - | |
| 8.97% | 842 M€ | +5.03% | ||
| 8.90% | 317 M€ | -.--% | - | |
| 8.85% | 486 M€ | +4.85% | - | |
| 7.29% | 1,026 M€ | +12.13% | ||
| 5.57% | 26 M€ | +9.53% | - | |
| 5.23% | 457 M€ | +10.05% | ||
| 5.18% | 7 M€ | +4.74% | - | |
| 5.16% | 10 M€ | +13.87% | ||
| 5.11% | 1,201 M€ | +7.84% | ||
| 5.09% | 9 M€ | +5.47% | ||
| 5.07% | 149 M€ | -.--% | - | |
| 4.93% | 74 M€ | +7.11% | ||
| 4.93% | 64 M€ | +11.43% | - |
Novartis AG is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- pharmaceutical products (81.7%): used to treat cardiovascular, respiratory, and dermatological diseases, gastrointestinal disorders, cancers, central nervous system disorders, hormone imbalances, etc.;
- generic drugs (18.3%; Sandoz).
Net sales are distributed geographically as follows: Europe (36.5%), the United States (34.9%), Asia/Africa/Australasia (20.9%), Canada and Latin America (7.7%).
Sector
Pharmaceuticals
Calendar
2024-01-07
- JPMorgan Healthcare Conference
Trading Rating :
Investor Rating :
ESG Refinitiv :
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
20
Last Close Price
97.09USD
Average target price
105.75USD
Spread / Average Target
+8.92%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +1.21% | 200 B $ | |
| +61.07% | 530 B $ | |
| +44.65% | 438 B $ | |
| -11.34% | 377 B $ | |
| -4.79% | 268 B $ | |
| -9.42% | 258 B $ | |
| -9.43% | 198 B $ | |
| -43.81% | 163 B $ | |
| +2.55% | 144 B $ | |
| -4.22% | 117 B $ |
- Stock
- Equities
- Stock Novartis AG - Swiss Exchange
- Funds and ETFs Novartis AG
